1116 related articles for article (PubMed ID: 9272128)
1. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
2. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
4. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
[TBL] [Abstract][Full Text] [Related]
5. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic approaches to reversing multidrug resistance.
Sikic BI
Semin Hematol; 1997 Oct; 34(4 Suppl 5):40-7. PubMed ID: 9408960
[TBL] [Abstract][Full Text] [Related]
7. [SDZ PSC 833: a novel modulator of MDR].
Covelli A
Tumori; 1997; 83(5 Suppl):S21-4. PubMed ID: 9446255
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
Lum BL; Fisher GA; Brophy NA; Yahanda AM; Adler KM; Kaubisch S; Halsey J; Sikic BI
Cancer; 1993 Dec; 72(11 Suppl):3502-14. PubMed ID: 7902206
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
11. A pharmacodynamic study of the P-glycoprotein antagonist CBT-1® in combination with paclitaxel in solid tumors.
Kelly RJ; Robey RW; Chen CC; Draper D; Luchenko V; Barnett D; Oldham RK; Caluag Z; Frye AR; Steinberg SM; Fojo T; Bates SE
Oncologist; 2012; 17(4):512. PubMed ID: 22416063
[TBL] [Abstract][Full Text] [Related]
12. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia.
Grey MR; Burgess R; Fisher A; Yin JA
Leuk Res; 1999 Jan; 23(1):29-35. PubMed ID: 9933132
[TBL] [Abstract][Full Text] [Related]
13. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Jiang XR; Kelsey SM; Wu YL; Newland AC
Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
[TBL] [Abstract][Full Text] [Related]
14. SDZ PSC-833--a novel potent in vitro chemosensitizer in multiple myeloma.
Jonsson B; Nilsson K; Nygren P; Larsson R
Anticancer Drugs; 1992 Dec; 3(6):641-6. PubMed ID: 1363199
[TBL] [Abstract][Full Text] [Related]
15. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.
Lum BL; Gosland MP
Hematol Oncol Clin North Am; 1995 Apr; 9(2):319-36. PubMed ID: 7642466
[TBL] [Abstract][Full Text] [Related]
16. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
Lopes EC; Scolnik M; Alvarez E; Hajos SE
Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressors as multidrug resistance reversal agents.
Morjani H; Madoulet C
Methods Mol Biol; 2010; 596():433-46. PubMed ID: 19949935
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma.
Cagliero E; Ferracini R; Morello E; Scotlandi K; Manara MC; Buracco P; Comandone A; Baroetto Parisi R; Baldini N
Oncol Rep; 2004 Nov; 12(5):1023-31. PubMed ID: 15492788
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
20. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype.
Lopes EC; Garcia M; Benavides F; Shen J; Conti CJ; Alvarez E; Hajos SE
Leuk Res; 2003 May; 27(5):413-23. PubMed ID: 12620293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]